GLYvantix Partner Service Terms & Conditions

GLYvantix Research, an arm of GLYvantix™, and the partner entity (“Partner”) share the goal of improving the safety of the peptides and sovereign health market. GLYvantix's role is to orchestrate efforts and coordinate stakeholders, in part through independent testing, transparent reporting, and data-driven insights. GLYvantix helps and supports Partners working towards this same goal.

Partner agrees to comply with GLYvantix policies, which may be updated or modified at GLYvantix's sole discretion. This includes any policy designed to protect the integrity of the GLYvantix scoring system, rating methodology, and database. Policy updates will be communicated on the GLYvantix website and become effective immediately.

GLYvantix owns all the data generated from testing, including test results, reports, and derived insights. GLYvantix decides whether and how to publish this data.

Unless covered by a separate confidentiality agreement, any information Partner supplies may be published. Do not provide trade secrets or other protected information unless expressly agreed otherwise.

In principle, GLYvantix does not collect or publish personal data about individuals. Partner should not provide GLYvantix any personal data.

Partner may not use or distribute GLYvantix's copyrighted materials, or laboratory Certificates of Analysis, except as expressly authorized. Authorized uses must preserve the integrity and context of the original material. Authorization to use content does not constitute an endorsement of any product or service.

Partner may not claim affiliation, endorsement, or partnership with GLYvantix beyond what has been explicitly agreed in joint written communications. All marketing or customer communications must describe the relationship accurately.

The GLYvantix Methodology for testing samples, scoring tests, and rating products and vendors (the “GLYvantix Methodology”) is proprietary and may evolve over time. Partner acknowledges that:

• • GLYvantix's role is to evaluate products available in the market and publish findings that reflect the state of products as they are encountered by the public.
• • Ratings, scores, and commentary are expressions of opinion based on disclosed methodology and underlying test data, not statements of undisputed fact or guarantees.
• • All testing is conducted in good faith, using independent laboratories and transparent reporting practices.
• • GLYvantix publishes these evaluations in the public interest, to advance product safety and transparency, not to disparage or defame any particular Partner.

Partner agrees that so long as GLYvantix follows its methodology and acts in good faith, GLYvantix's publication of ratings, test results, or commentary does not constitute libel, defamation, or other actionable harm, even if Partner disagrees with the conclusions or experiences commercial impact.

Partner must not manipulate or misrepresent customer engagement with GLYvantix. This includes directly submitting or indirectly encouraging fraudulent submissions (“astroturfing”), inducements to customers to submit specific samples (customers should always have a choice of sample to send to GLYvantix), or any practice intended to distort testing or ratings.

Both GLYvantix and Partner commit to act in good faith. GLYvantix will apply its methodology fairly and consistently across all Partners and will investigate any claim of data error supported by evidence. GLYvantix will investigate Partner claims regarding incorrect data and will make publicly documented corrections when warranted.

If Partner believes published data is inaccurate or otherwise objects to GLYvantix's handling of a matter, Partner may invoke GLYvantix's appeals process. The appeals process is designed to provide a fair review, with clear documentation of Partner's claim and GLYvantix's response. If the appeal shows an error, GLYvantix will make appropriate corrections, and such corrections will be publicly documented. Use of the appeals process is required before pursuing any formal dispute or litigation.

Transparency is a core principle of GLYvantix's work. GLYvantix is committed to publishing test results and related insights openly, and to resisting any attempts by market stakeholders including laboratories, manufacturers, or government regulators to suppress or distort truthful information.

These Partner Service Terms are governed by the laws of England and Wales. Any dispute shall be resolved exclusively in the courts of England and Wales.

For Partners outside the United Kingdom:

• • Communication will be in English.
• • Compliance with local laws and regulations is Partner's responsibility.
• • All transactions are in U.S. Dollars unless agreed otherwise.
• • Partner acknowledges that GLYvantix Research, an arm of GLYvantix™, operates under the laws of the United Kingdom (England and Wales).

GLYvantix's liability to Partner is capped at the total fees Partner paid in the twelve months preceding any claim. Neither party is liable for indirect, incidental, or consequential damages. This limitation does not apply to cases of fraud or willful misconduct.

Both GLYvantix and Partner will use their best efforts to meet obligations under this Agreement. If circumstances outside a party's reasonable control make performance temporarily impossible despite such efforts, that party will not be held liable for the resulting delay or failure, but will promptly resume performance once conditions allow.

If Partner breaches these Terms or any related agreement, GLYvantix may immediately terminate ongoing work, suspend further services, and refuse new engagements. In line with GLYvantix's mission of transparency and public safety, GLYvantix may also publish information about the breach to the extent it is relevant to public risk, product safety, or market integrity.

This Agreement remains in effect until terminated by either party with thirty (30) days' written notice. Termination does not affect GLYvantix's right to retain and publish previously generated data or Partner's obligations that survive termination.

Partner acknowledges and agrees that GLYvantix will not accept requests for test results removal or data deletion once results are published. All published test results and ratings remain permanently available on the GLYvantix platform.

GLYvantix may update these Partner Service Terms with thirty (30) days' notice. Updates apply only to new business entered into after the effective date of the revised Partner Service Terms. Partner may opt out by terminating before entering new business. Continuing to engage GLYvantix services after the notice period means acceptance of the revised Partner Service Terms.

These Partner Service Terms, together with any Statement of Work, invoice, or other written agreement expressly referencing these Partner Service Terms, form the entire agreement between GLYvantix and Partner. They supersede all prior discussions or understandings on the same subject. In the event of a conflict, the specific terms in a Statement of Work or invoice will prevail over these general Partner Service Terms, but only with respect to the subject matter of that document.